Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
6.94
+0.19 (2.81%)
Apr 8, 2026, 9:56 AM EDT - Market open
Relmada Therapeutics Analyst Ratings
Total Analysts
5
Consensus Rating
Strong Buy
Price Target
$12.40
Upside
+78.67%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $12 | Buy | Initiates | $12 | +72.91% | Mar 24, 2026 |
| Mizuho | Mizuho | Buy Maintains $10 → $19 | Buy | Maintains | $10 → $19 | +173.78% | Mar 20, 2026 |
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +101.73% | Mar 2, 2026 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $8 | Hold → Buy | Upgrades | $8 | +15.27% | Jan 23, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +29.68% | Dec 22, 2025 |
| Mizuho | Mizuho | Hold → Buy Upgrades $1 → $10 | Hold → Buy | Upgrades | $1 → $10 | +44.09% | Nov 19, 2025 |
| Mizuho | Mizuho | Buy → Hold Downgrades $23 → $1 | Buy → Hold | Downgrades | $23 → $1 | -85.59% | Dec 5, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $1 | Buy → Hold | Downgrades | $10 → $1 | -85.59% | Dec 4, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $3.5 → $13 | Hold → Strong Buy | Upgrades | $3.5 → $13 | +87.32% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $3 → $2 | Hold → Strong Sell | Downgrades | $3 → $2 | -71.18% | Jun 5, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +274.64% | Jun 15, 2023 |
| SVB Leerink | SVB Leerink | Buy Maintains $42 → $10 | Buy | Maintains | $42 → $10 | +44.09% | Jan 23, 2023 |
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $8 | Strong Buy → Hold | Downgrades | $8 | +15.27% | Oct 14, 2022 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 14, 2022 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 13, 2022 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $49 → $81 | Strong Buy | Maintains | $49 → $81 | +1,067.15% | Sep 23, 2022 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.